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Surgerya b s t r a c t
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy &
Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on
endometrial cancer was held on 11–13 December 2014 in Milan, Italy, and comprised a multidisciplinary
panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert
panel prepared three clinically-relevant questions about endometrial cancer relating to the following four
areas: Prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All rel-
evant scientific literature, as identified by the experts, was reviewed in advance. During the consensus
conference, the panel developed recommendations for each specific question and a consensus was
reached. Results of this consensus conference, together with a summary of evidence supporting each rec-
ommendation, are detailed in this article. All participants have approved this final article.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 117 (2015) 559–581
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Key message
 This ESMO–ESGO–ESTRO consensus conference manuscript was
compiled by a multidisciplinary panel of 40 experts.
 It addresses clinically-relevant questions regarding prevention,
screening, surgery, adjuvant therapy and management of
advanced/recurrent endometrial cancer, and complements the
ESMO clinical practice guidelines. Recommendations provided are accompanied by relevant
supporting evidence.
Introduction
Endometrial cancer is the most common gynaecological cancer
in developed countries. The number of newly diagnosed cases in
Europe was nearly 100,000 in 2012, with an age standardised inci-
dence of 13.6 per 100,000 women. Cumulative risk of a diagnosis of
endometrial cancer is 1.71% [1].
More than 90% of cases of endometrial cancer occur in women
>50 years of age, with a median age at diagnosis of 63 years. How-
ever, 4% of women with endometrial cancer are younger than
40 years old [2], many of whom still wish to retain their fertility.
The majority of endometrial cancers are diagnosed early (80% in
stage I), with five-year survival rates of over 95%. However, five-
year survival rates are much lower if there is regional spread or
distant disease (68% and 17%, respectively) [3].
Historically, endometrial carcinoma has been classified into two
main clinicopathological and molecular types: Type I is the much
560 Endometrial cancer consensus conference guidelinesmore common endometrioid adenocarcinoma (80–90%) and Type
II comprises non-endometrioid subtypes such as serous, clear cell
and undifferentiated carcinomas, as well as carcinosarcoma/
malignant-mixed Müllerian tumour (10–20%) [4]. Molecular data
in support of this dichotomous classification have become an inte-
gral component of pathologic evaluation, as type I carcinomas are
preferentially associated with genetic alterations in PTEN, KRAS,
CTNNB1 and PIK3CA and MLH1 promoter hypermethylation,
whereas serous carcinomas prototypically harbour TP53 muta-
tions. However, this dualistic model has limitations as considerable
molecular heterogeneity exists; for example, 25% of high grade
endometrioid carcinomas express mutated TP53 and behave like
serous carcinomas [5]. Extensive work performed by The Cancer
Genome Atlas (TCGA) Research Network has significantly
improved our understanding of the molecular landscape of
endometrial cancer, introducing not 2, but 4 molecular subtypes
including: (1) POLE (ultramutated) tumours, (2) microsatellite
unstable tumours, (3) copy-number high tumours with mostly
TP53 mutations and (4) remaining group without these alterations
[6]. Hereditary endometrial adenocarcinomas are mostly seen in
families with hereditary non-polyposis colon cancer (HNPCC,
Lynch syndrome [LS]). Although the majority of endometrial carci-
nomas related to LS are Type I cancers, the proportion of Type II
cancers seems to be higher than in the case of sporadic endome-
trial carcinoma [7].
Although the majority of cases of endometrial cancer are diag-
nosed at an early stage, differences in patient characteristics and
histopathological features of the disease impact both on patient
prognosis and the recommended treatment approach. Given the
large body of literature available that addresses the management
of endometrial cancer, the aim of this consensus conference was
to produce multidisciplinary evidence-based guidelines on
selected clinically-relevant questions in order to complement the
already-available European Society for Medical Oncology (ESMO)
Clinical Practice Guidelines (CPG) for the diagnosis, treatment
and follow-up of patients with endometrial cancer [8].
Methods
In 2014, ESMO decided to update the clinical recommendations
for endometrial cancer using a consensus conference approach.
The consensus panel comprised 40 experts in the management of
endometrial cancer, and included representation from the Euro-
pean SocieTy for Radiotherapy & Oncology (ESTRO), the European
Society of Gynaecological Oncology (ESGO) and ESMO. Each panel
member was assigned to one of four working groups, with a work-
ing group chair and co-chair appointed for each group. Three con-
sensus conference chairs (N. Colombo, C. Creutzberg, C. Sessa) were
also appointed.
Each working group was assigned a subject area as follows:
1. Prevention and screening of endometrial cancer (Chair: F.
Amant; Co-Chair: T. Bosse).
2. Surgery (Chair: C Marth; Co-Chair: D. Querleu).
3. Adjuvant treatment (Chair: R. Nout; Co-Chair: M.R. Mirza).
4. Advanced and recurrent disease (Chair: J. Ledermann; Co-Chair:
A. González-Martín).
The consensus conference was held on 11–13 December 2014
in Milan, Italy. Before this consensus conference, three clinically-
relevant questions were identified for each subject area/working
group, giving a total of 12 clinically-relevant questions as follows:
1. Which surveillance should be used for asymptomatic
women?2. What work-up and management scheme should be under-
taken for fertility preserving therapy in patients with atypi-
cal hyperplasia (AH)/endometrial intraepithelial neoplasia
(EIN) and grade 1 endometrioid endometrial cancer (EEC)?
3. Which (molecular) markers can help distinguish (pre)-
cancerous lesions from benign mimics?
4. How does the medical condition influence surgical
treatment?
5. What are the indications for and to what extent is lym-
phadenectomy indicated in the surgical management of
endometrial cancer?
6. How radical should the surgery be in different stages and
pathological subtypes of endometrial cancer?
7. What is the current best definition of risk groups for adju-
vant therapy?
8. What are the best evidence-based adjuvant treatment
strategies for patients with low- and intermediate-risk
endometrial cancer?
9. What are the best evidence-based adjuvant treatment
strategies for patients with high-risk endometrial cancer?
10. Does surgery or radiotherapy (RT) have a role in advanced or
recurrent endometrial cancer?
11. What are the optimal systemic therapies for advanced/
recurrent disease?
12. What are the most promising targeted agents and which
study designs should be used to evaluate their clinical
benefit?
Each working group was responsible for reviewing the relevant
literature in order to draft preliminary recommendations relating
to each of their assigned questions. No systematic literature search
was undertaken. During the conference, in parallel sessions, the
four working groups discussed and reached agreement on recom-
mendations relating to each of their assigned questions. Recom-
mendations from each group were then presented to the entire
panel of experts, where they were discussed and modified as
required. An adapted version of the ‘Infectious Diseases Society
of America-United States Public Health Service Grading System’
was used (Table 1 [9]) to define the level of evidence and strength
of each recommendation proposed by the group. Finally, a vote was
conducted to determine the level of agreement among the expert
panel for each of the recommendations. Panel members were
allowed to abstain from voting in cases where they either had
insufficient expertise to agree/disagree with the recommendation
or if they had a conflict of interest that could be considered as
influencing their vote.
Results of this consensus conference, together with a summary
of evidence supporting each recommendation, are detailed in this
article, and a summary of all recommendations is included in sup-
plementary Table S1. However, these additional recommendations
for specific clinical situations should be read in conjunction with
the ESMO CPG for the diagnosis, treatment and follow-up of
patients with endometrial cancer [8].Results
Prevention and screening of endometrial cancer
Risk factors for endometrial cancer
Most patients with endometrial cancer have an identifiable
source of excess oestrogen and typically display a characteristic
clinical profile comprising a high body mass index (BMI) that is
considered as overweight (BMI 25–30) or obese (BMI 30), often
with other components of metabolic syndrome (e.g. hypertension,
diabetes). The evidence that greater body fatness (reflected by BMI,
Table 1
Levels of evidence and grades of recommendation.
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good
methodological quality (low potential for bias) or meta-analyses of well-
conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of
bias (lower methodological quality) or meta-analyses of such trials or of
trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly
recommended
B Strong or moderate evidence for efficacy but with a limited clinical
benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or
the disadvantages (adverse events, costs, ...), optional
D Moderate evidence against efficacy or for adverse outcome, generally not
recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
By permission of the Infectious Diseases Society of America-United States Public
Health Service Grading System [9].
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endometrial cancer is convincing. Glycaemic load is probably a
cause of endometrial cancer, while the evidence suggesting that
sedentary habits (marked by sitting time) and adult attained
height are causes of endometrial cancer is limited [10].
High BMI correlates with good prognostic features of endome-
trial cancer, including low tumour grade, endometrioid histology
and presentation at early stage. In a small subset of patients, the
pathogenesis is related to mismatch repair abnormality and LS.
Tumours associated with mismatch repair abnormalities and LS
appear to be distinct, with worse prognostic factors and worse clin-
ical outcome [11].
According to a recent meta-analysis involving six studies and
3132 cancer cases, relative risk (RR) for developing endometrial
cancer in women with metabolic syndrome is 1.89 (95% confidence
interval [CI] 1.34–2.67, P = <0.001). According to individual compo-
nents of metabolic syndrome, obesity is associated with the great-
est increase in RR of 2.21 (P = <0.001) [12]. The strength of
association between obesity and cancer risk increases with
increasing BMI: RR for overweight is 1.32 (95% CI 1.16–1.50) and
for obesity is 2.54 (95% CI 2.11–3.06) [13]. Other components of
the metabolic syndrome linked to endometrial cancer include
hypertension, with a RR of 1.81 (P = 0.024) [12] or an odds ratio
(OR) of 1.77 (1.34–2.34) [14]. Hypertriglyceridaemia has a weaker
but still significant association (RR 1.17, P < 0.001) [12].
Diabetes mellitus, in particular type II, has long been held as an
independent risk factor for endometrial cancer, with an approxi-
mate doubling of risk (OR 2.1; 95% CI 1.40–3.41), [14]. However,
the fact that people with type II diabetes mellitus (T2DM) tend
to be obese is a confounding factor, and a recent epidemiological
study from the United States questioned the independent role of
T2DM as a risk factor for endometrial cancer [15].
Nulliparity and infertility are also classical risk factors for
endometrial cancer. Among the causes of infertility, polycystic
ovarian syndrome (PCOS) seems to be the most important, with
an almost 3-fold increase in risk (OR 2.79–2.89) [16]. However,
as with diabetes, obesity seems to be a confounding factor, and
the BMI-adjusted OR is lower (2.2; 95% CI 0.9–5.7) [17].
Other risk factors for endometrial cancer include unopposed
oestrogen therapy, oestrogen-producing tumours and early menar-
che/late menopause. Unopposed oestrogen therapy increases therisk for endometrial cancer 10- to 30-fold if treatment continues
5 years or more [18]. Oestrogen-producing tumours, or ovarian
granulosa, and theca cell tumours carry an increased risk for
endometrial cancer, with up to 20% of women with these tumours
reported as having a simultaneous endometrial cancer [19]. Both
early menarche and late menopause are associated with a 2-fold
increased risk for endometrial cancer. The RR is 2.4 for women
<12 vsP15 years [20] and is 1.8 for womenP55 vs <50 years [21].
Studies of women with breast cancer taking tamoxifen with
therapeutic or preventive intent have shown that the RR of devel-
oping endometrial cancer is 2.53 times higher than that of an age
matched population. This risk differs depending on menopausal
status. Premenopausal women treated with tamoxifen have no
known increased risk of endometrial cancer, while this risk in post-
menopausal women is 4.0 (95% CI 1.70–10.90) [22]. The level of
risk of endometrial cancer is also dose and time dependent.
LS or HNPCC is an autosomal dominant inherited disorder
caused by germline mutations in DNA mismatch repair genes.
Women with mutations in MLH1, MSH2, MSH6 or PMS2 have up
to a 40–60% lifetime risk of developing both endometrial and col-
orectal cancers, as well as a 9–12% lifetime risk of developing ovar-
ian cancer [23].
Screening and prevention of endometrial cancer
Most cases of endometrial cancer cannot be prevented, but
reducing the risk factors and introducing protective factors into
the lifestyle whenever possible, may lower the risk of developing
this disease.
All women should be told about the risks and symptoms of
endometrial cancer and be strongly encouraged to engage in regu-
lar physical activity (exercise) and adopt an active lifestyle which
can help to attain and maintain a healthy weight as well as lower-
ing the risk of other risk factors for endometrial cancer such as high
blood pressure and diabetes. The use of combined oral contracep-
tives is significantly associated with decrease in endometrial can-
cer in ever users, a benefit that is greater with increasing
duration of use.
1. Which surveillance should be used for asymptomatic
women?
Women with average risk for endometrial cancer
There is no indication that population-based screening has a role
in the early detection of endometrial cancer amongwomenwho are
at average endometrial cancer risk and have no symptoms. There is
also no standard or routine screening test for endometrial cancer.
Screening of asymptomatic women for endometrial carcinoma
has in general been recommended only for those with LS [24,25].
There is no evidence that screening by ultrasonography (e.g.
endovaginal or transvaginal ultrasound) reduces mortality from
endometrial cancer. Moreover, cohort studies indicate that screening
asymptomatic women will result in unnecessary additional biopsies
because of false-positive test results. Risks associated with false-
positive tests include anxiety and complications from biopsies [26].
At the time of menopause, women should be strongly encour-
aged to report any vaginal bleeding, discharge or spotting to their
doctor to ensure they receive appropriate treatment of any precan-
cerous disorders of the endometrium.
Recommendation 1.1. There is no evidence for endometrial
cancer screening in the general populationLevel of evidence: II
Strength of recommendation: A
Consensus: 100% yes (37 voters)
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Women at increased risk for endometrial cancer due to a his-
tory of unopposed oestrogen therapy, late menopause, tamox-
ifen therapy, nulliparity, infertility or failure to ovulate,
obesity, diabetes or hypertension should be informed of the
risks and symptoms of endometrial cancer and strongly encour-
aged to report any unexpected bleeding or spotting to their
physicians.
Asymptomatic women with risk factors for endometrial cancer
who have endometrial thickening and other positive findings on
ultrasound, such as increased vascularity, inhomogeneity of the
endometrium, particulate fluid or thickened endometrium over
11 mm should be managed on a case-by-case basis. The potential
benefits, risks and limitations of testing for early endometrial can-
cer should be explained in order to ensure informed decision-
making about testing.
Premenopausal women treated with tamoxifen do not require
additional monitoring beyond routine gynaecological care. Post-
menopausal women taking tamoxifen should be informed about
symptoms of endometrial hyperplasia or cancer [27].
Although findings from a recently published meta-analysis have
verified the efficacy of the levonorgestrel intrauterine device (LNG-
IUD) in preventing de novo polyps in breast cancer patients treated
with tamoxifen, there was insufficient evidence to ascertain
whether the LNG-IUD was associated with any benefit in reducing
the incidence of precancerous or cancerous lesions [28].
Recommendation 1.2. Unopposed oestrogen treatment should
not be started or should be discontinued in women with a uterus
in situLevel of evidence: III
Strength of recommendation: A
Consensus: 100% yes (37 voters)Recommendation 1.3. Routine surveillance in asymptomatic
women with obesity, PCOS, diabetes mellitus, infertility, nullipar-
ity or late menopause is not recommendedLevel of evidence: III
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 1.4. For women with adult granulosa cell
tumour, if hysterectomy has not been performed, endometrial
sampling is recommended. If this shows no evidence of (pre)malig-
nancy, no further screening for endometrial malignancies is
requiredLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 1.5. In patients with epithelial ovarian cancer
undergoing fertility sparing treatment, endometrial sampling is
recommended at the time of diagnosisLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 1.6. Routine screening for endometrial cancer
in asymptomatic tamoxifen users is not recommendedLevel of evidence: III
Strength of recommendation: B
Consensus: 94.6% (35) yes, 5.4% (2) abstain (37 voters)Women with high risk for endometrial cancer
Women with a high risk for endometrial cancer include
known carriers of HNPCC-associated genetic mutations, those
who have a substantial likelihood of being a mutation carrier
(i.e. a mutation is known to be present in the family), and
women without genetic testing results but who are from
families with a suspected autosomal dominant predisposition
to colon cancer.
Findings from a prospective observational cohort study of
women with LS opting for endometrial cancer screening and who
underwent annual outpatient hysteroscopy and endometrial
sampling (OHES) suggest that in women with LS, annual OHES is
acceptable and has high diagnostic accuracy in screening
for endometrial cancer and atypical endometrial hyperplasia
(AEH) [29]. However, larger international studies are needed for
confirmation.
Women with an HNPCC-associated mutation or with a substan-
tial likelihood of having an HNPCC-associated mutation should be
informed of the potential benefits, risks and limitations of testing
for early endometrial cancer; they should also be informed that
the recommendation for screening is based on expert opinion in
the absence of definitive scientific evidence.
Although there is insufficient evidence to endorse annual
screening for endometrial cancer in this group, annual screening
beginning at age 35 is recommended due to the high risk of
endometrial cancer and the potentially life-threatening nature of
this disease. As screening will be of limited efficacy in gynaecolog-
ical cancers (endometrial and ovarian), once the family is com-
pleted, particularly by age 35–40 years, careful consideration
must be given to the option of prophylactic hysterectomy and
bilateral salpingo-oophorectomy [30].
In women with LS, the following options are available:
 Annual screening beginning at age 35 (recommended).
 Regular hysteroscopy and endometrial biopsies or hysterec-
tomy (current options).
 The application of local progesterone using the LNG-IUD.
 Treatment of premalignant disease (AEH, EIN).
 Hysterectomy and bilateral oophorectomy.
Evaluating the likelihood of a patient having a gynaecological
cancer predisposition syndrome enables the physician to provide
individualised assessments of cancer risk, aswell as the opportunity
to offer tailored screening and prevention strategies such as surveil-
lance, chemoprevention and prophylactic surgery that may reduce
the morbidity and mortality associated with these syndromes.
Recommendation 1.7. Surveillance of the endometrium by
gynaecological examination, transvaginal ultrasound and aspira-
tion biopsy starting from the age of 35 years (annually until
hysterectomy) should be offered to all LS mutation carriersLevel of evidence: IV
Strength of recommendation: B
Consensus: 97.3% (36) yes, 2.7% (1) abstain (37 voters)Recommendation 1.8. Prophylactic surgery (hysterectomy and
bilateral salpingo-oophorectomy), preferably using a minimally
invasive approach, should be discussed at the age of 40 as an
option for LS mutation carriers to prevent endometrial and ovarian
cancer. All pros and cons of prophylactic surgery must be discussedLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)
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undertaken for fertility preserving therapy in patients with AH/
EIN and grade 1 EEC?
Work-up for fertility preserving therapy
The diagnosis of endometrial carcinoma in young women of
childbearing age is rare. Indeed, only 4% of patients with endome-
trial carcinoma are less than 40 years of age [2]. Younger and pre-
menopausal women with endometrial carcinoma seem to have a
better prognosis than older patients, with increased rates of early
stage and low grade disease reported [2,31,32].
The standard approach for the management of endometrial can-
cer in young women of childbearing age is hysterectomy and bilat-
eral salpingo-oophorectomy with or without lymphadenectomy.
Although this is a highly effective approach, carrying a 5-year sur-
vival rate of 93%, it also results in a permanent loss of reproductive
potential. Conservative management of endometrial carcinoma is
based on medical treatment with oral progestins. The most impor-
tant issues when considering a conservative management
approach are the assessment of clinical and pathological character-
istics of the tumour and selection of the appropriate medical
intervention.
A conservative management approach could be considered in
patients with a histological diagnosis of grade 1 endometrial carci-
noma (or premalignant disease such as AH) [31]. The optimal
method to obtain these histologic characteristics is dilatation and
curettage (D&C) [33]; this procedure is superior to pipelle biopsy
in terms of accuracy of the tumour grade [34].
The histological diagnosis should be reviewed by an expert
pathologist to improve the accuracy of histological assessment
(endometrial carcinoma or AH) and the reliability of tumour grad-
ing [35], whereas the initial stage should be confirmed by
enhanced pelvic magnetic resonance imaging (MRI) to exclude
overt myometrial invasion, as well as adnexal or pelvic node
involvement [36]. Patients should be informed that this is a non-
standard approach and they should be willing to accept close
follow-up during and after the treatment. They should also be
informed of the need for future hysterectomy in case of failure of
the treatment and/or after pregnancies.
Recommendation 2.1. Patients with AH/EIN or grade 1
endometrioid endometrial cancer requesting fertility preserving
therapy must be referred to specialised centresLevel of evidence: V
Strength of recommendation: A
Consensus: 100% yes (37 voters)
Recommendation 2.2. In these patients, D&C with or without
hysteroscopy must be performedLevel of evidence: IV
Strength of recommendation: A
Consensus: 97.3% (36) yes, 2.7% (1) abstain (37 voters)
Recommendation 2.3. AH/EIN or grade 1 EEC must be con-
firmed/diagnosed by a specialist gynaecopathologistLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)
Recommendation 2.4. Pelvic MRI should be performed to exclude
overt myometrial invasion and adnexal involvement. Expert
ultrasound can be considered as an alternativeLevel of evidence: III
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 2.5. Patients must be informed that fertility-
sparing treatment is a non-standard treatment and the pros and
cons must be discussed. Patients should be willing to accept close
follow-up and be informed of the need for future hysterectomyLevel of evidence: V
Strength of recommendation: A
Consensus: 97.3% (36) yes, 2.7% (1) abstain (37 voters)
Management schemes for fertility-preserving therapy
Conservative medical treatment for endometrial cancer is based
on progestins with medroxyprogesterone acetate (MPA; 400–
600 mg/day) or megestrol acetate (MA; 160–320 mg/day) [33].
Fewpapers have addressed the use of LNG-IUDbut preliminary data
using such treatment (added to gonadotropin-releasing hormone
[GnRH] analogues) seem to demonstrate similar remission and
recurrence rates as oral progestins [37]. Assessment of response
must be performed at 6 months with a new D&C and imaging [38].
Response rates associated with the conservative management
of endometrial carcinoma are around 75% [39,40], but recurrence
rates are 30–40% [39,41,42]. Standard surgery with hysterectomy
should be proposed to non-responders while maintenance treat-
ment for a further 6 months can be considered in responders
who wish to delay pregnancy [33].
Although progesterone receptor (PgR) status is a reliable
predictive factor for disease remission, a routine check is not
recommended since 50% of PgR negative patients will respond to
treatment [43].
Pregnancy is associated with a reduced risk for endometrial
cancer recurrence [40]. Findings from recent meta-analyses
showed that the pooled live birth rate among women receiving
fertility-preserving treatment for endometrial cancer was 28%,
and reached 39% when assisted reproduction technology was used
[39,44]. Thus, for patients achieving a complete response at
6 months, conception must be encouraged and these patients
should be referred to a fertility clinic.
For patients with disease recurrence after an initial response,
hysterectomy should be proposed as the first option. Moreover,
given the high rate of recurrence, after completion of childbearing
(or after the age of potential pregnancy), standard treatment with
hysterectomy and salpingo-oophorectomy is recommended.
Preservation of the ovaries can be considered in selected cases,
depending on the patient’s age and genetic risk factors.
Recommendation 2.6. For patients undergoing fertility-
preserving therapy, MPA (400–600 mg/day) or MA (160–320 mg/-
day) is the recommended treatment. However, treatment with
LNG-IUD with or without GnRH-analogues can also be consideredLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 2.7. In order to assess response, D&C, hys-
teroscopy and imaging at 6 months must be performed. If no
response is achieved after 6 months, standard surgical treatment
should be performedLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 2.8. In case of complete response, conception
must be encouraged and referral to a fertility clinic is recommendedLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)
ensus conference guidelinesRecommendation 2.9. Maintenance treatment should be consid-
ered in responders who wish to delay pregnancyLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)
564 Endometrial cancer consRecommendation 2.10. Patients not undergoing hysterectomy
should be re-evaluated clinically every 6 monthsLevel of evidence: IV
Strength of recommendation: B
Consensus: 97.3% (36) yes, 2.7% (1) abstain (37 voters)Recommendation 2.11. After completion of childbearing, a hys-
terectomy and salpingo-oophorectomy should be recommended.
The preservation of the ovaries can be considered depending on
age and genetic risk factorsLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)
3. Which (molecular) markers can help distinguish
(pre)cancerous lesions from benign mimics?
Differential diagnosis between benign uterine lesions and
endometrial (pre)carcinomas is based mainly on morphological
criteria but may be supported by additional immunohistochemical
(IHC) markers and molecular alterations in problematic cases [45].
Currently, AH/EIN is the preferred terminology of the precursor
lesion of the most common type of endometrial carcinoma,
endometrioid carcinoma, including its variants.
Recommendation 3.1. In case of uncertainty low threshold refer-
ral to a specialised gynaecopathologist is recommendedLevel of evidence: V
Strength of recommendation: A
Consensus: 100% yes (37 voters)
The differential diagnosis of AH/EIN includes, in particular,
endometrial hyperplasia without atypia, but also includes other
mimics, such as glandular and stromal breakdown, focal glandular
crowding and epithelial metaplasias (e.g. hypersecretory changes).
Loss of PTEN expression, mostly by mutation, and loss of PAX-2 by
downregulation [46–48], are the only immunohistochemical
markers that have been sufficiently studied and can be used on
curettage material. Loss of PTEN occurs in 40–50% of AH/EIN cases,
whereas loss of PAX-2 occurs in 70% of AH/EIN, and a joint loss of
PTEN and PAX-2 occurs in around 30% of AH/EIN [49–51].
Recommendation 3.2. PTEN and PAX-2 IHC is recommended to
distinguish AH/EIN from benign mimics. Other markers that can be
used in this context are MLH1 and ARID1a by IHCLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)
Another histological entity that may arise in the differential
diagnosis of AH/EIN is the rare atypical polypoid adenomyoma
(APA), for which there are no IHC stains with practical value.
Recommendation 3.3. IHC is not recommended to distinguish
APA from AH/EINLevel of evidence: V
Strength of recommendation: B
Consensus: 100% yes (37 voters)The putative precursor of serous carcinoma, serous endometrial
intraepithelial carcinoma (SEIC), is consideredanon-invasive cancerrather than a precancer since it may be associated with extensive
extrauterine disease [9]. Molecular alterations of serous carcinoma
are already present in SEIC, which is especially true for p53 expres-
sion [52–54]. A completely negative immunoreactive pattern for
p53 (‘all or null’) is considered a surrogate for p53 mutation, and is
present in almost all SEIC and invasive serous carcinomas [55].
Recommendation 3.4. p53 by IHC is recommended to distinguish
SEIC from its mimicsLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)
In selected cases of endometrial cancer, clinical and radiological
work-up may not be conclusive about the endometrial origin of the
uterine tumour. In addition, endocervical, ovarian and endometrial
adenocarcinomas may show histopathological overlap. Several IHC
markers have been proposed for these differential diagnoses, but
these markers lack sensitivity or specificity to be used as single
markers. When endocervical origin is considered, the use of a panel
of markers, including carcinoembryonic antigen (CEA), vimentin,
oestrogen receptor (ER) and p16 (as surrogate for human papilloma
virus [HPV]), is recommended [56]. In case of p16 positivity, the
staining pattern should be taken into account. Diffuse p16 staining
is frequently seen in serous, clear cell and mucinous carcinoma
endometrial cancers [57,58]. In cases of scanty tissue with serous
carcinoma, an ovarian origin of the serous carcinoma should be con-
sidered. The most discriminatory marker for this differential diag-
nosis is Wilms tumour 1 gene (WT-1) [59], which is expressed in
80–100% of high-grade serous carcinomas of the ovary [60,61] com-
paredwith 7–20% in serous endometrial carcinomas [62,63]. In gen-
eral, the expression profile should be interpreted in the context of
the morphological subtype. An individual approach, with close cor-
relation between clinical presentation and morphological subtype,
is therefore recommended.
Recommendation 3.5. A panel of markers must be used in cases
where endocervical cancer is suspected. This panel should include
at least ER, vimentin, CEA and p16 by IHC, and needs to be assessed
in the histologic and clinical context. In addition, HPV analysis can
be consideredLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 3.6. WT-1 by IHC is the recommended marker
to determine the origin of serous cancerLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)Recommendation 3.7. Morphology (and not IHC) should be used
to distinguish AH/EIN from EECLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)
Surgery
4. How does the medical condition influence surgical
treatment?Mandatory pre-operative work-up
The consensus is based on current clinical practice. Family his-
tory is usually taken to identify risk factors associated with LS,
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belonging to the Lynch spectrum. General assessment and, if
appropriate, geriatric assessment are required in patients with
comorbidities and elderly patients, respectively, in order to adapt
the surgical strategy. Indeed, endometrial cancer is frequently
associated with obesity, hypertension and diabetes and, in some
patients, the extent of surgery or staging that is theoretically
required may not be feasible. In such cases, a benefit-risk assess-
ment of surgery may lead to an individualised decision to perform
a ‘non-standard’ surgery or a limited staging procedure.
Pelvic examination and pelvic ultrasonography are mandatory
components of clinical staging of endometrial cancer in order to
establish a tentative International Federation of Gynecology and
Obstetrics (FIGO) staging before definitive pathology. In addition
to being the first imaging technique used to evaluate abnormal
uterine bleeding, ultrasonography, preferably specialised ultra-
sonography [64], offers the possibility of evaluating the size of
the tumour, ruling out ovarian disease, and assessing myometrial
invasion and cervical stromal involvement [65].
Pre-operative pathological information is crucial for establish-
ing the surgical plan. First, all patients with a risk of cancer,
particularly patients with postmenopausal bleeding and a hyper-
plastic endometrium at ultrasound, should be investigated with
endometrial biopsy or curettage in order to (1) avoid uterine
morcellation, which poses a risk of spreading unsuspected cancer-
ous tissue, notably endometrial carcinomas or sarcomas, beyond
the uterus and may make the pathological assessment of myome-
trial invasion extremely difficult; and (2) prevent the discovery of
an unexpected malignancy after inadequate surgery (subtotal
hysterectomy and/or preservation of the ovaries in a post-
menopausal patient, incomplete staging). Second, as grading of
EEC has a significant prognostic impact [66] and various histotypes
of endometrial cancer harbour different natural histories, the
primary therapeutic strategy must be adapted to the information
provided by a pre-operative pathological examination, despite
the fact that discrepancies between pre-operative evaluation and
final pathology exist [67].
The final therapeutic strategy should be adapted according to
the information available before surgery, taking into account the
tentative stage (apparent stage I or more advanced stage), grade
(of endometrioid tumours; grade 1–3 or a binary system) and
histotype (endometrioid versus non-endometrioid tumour).
Recommendation 4.1. Mandatory work-up must include: Family
history; general assessment and inventory of comorbidities;
geriatric assessment, if appropriate; clinical examination, includ-
ing pelvic examination; transvaginal or transrectal ultrasound; and
complete pathology assessment (histotype and grade) of an
endometrial biopsy or curettage specimenLevel of evidence: V
Strength of recommendation: A
Consensus: 100% yes (37 voters)Recommendation 4.2. Extent of surgery should be adapted to the
medical condition of the patientLevel of evidence: V
Strength of recommendation: A
Consensus: 100% yes (37 voters)
Optional pre-operative work-up
Imaging
Additional imaging is considered according to the clinical situ-
ation. Computed tomography (CT) scan and/or positron emission
tomography (PET)-CT are options in clinically advanced endome-
trial cancer. In apparent stage I endometrial cancer, MRI may be
useful to complete information regarding myometrial invasion[65]. However, this applies only in institutions where the indica-
tion for lymph node dissection (LND) is tailored according to the
stratification of patients into low-, intermediate- and high-risk
groups. In this setting, specialised ultrasonography and/or
intra-operative pathological examination of the uterus may also
be considered [68].
Recommendation 4.3. In clinical stage I, grade 1 and 2: At least
one of the three following tools should be used to assess
myometrial invasion if LND is considered: Expert ultrasound
and/or MRI and/or intra-operative pathological examinationLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)
Recommendation 4.4. Other imaging methods (thoracic, abdom-
inal and pelvic CT scan, MRI, PET scan or ultrasound) should be
considered to assess ovarian, nodal, peritoneal ormetastatic diseaseLevel of evidence: IV
Strength of recommendation: C
Consensus: 94.6% (35) yes, 2.7% (1) abstain, 2.7% (1) no (37
voters)
Serum tumour markers
There is evidence that the serum tumour markers cancer anti-
gen 125 (CA-125) and, more recently, human epididymis protein
4, are significantly correlated with histological grade, stage, lymph
node metastases, myometrial invasion and cervical involvement
[69–71]. However, the appropriate cut-off has not been estab-
lished and evidence that serum marker assessment is clinically
useful is lacking.
Recommendation 4.5. There is no evidence for the clinical
usefulness of serum tumour markers, including CA-125Level of evidence: IV
Strength of recommendation: B
Consensus: 91.9% (34) yes, 5.4% (2) abstain, 2.7% (1) no (37
voters)
Surgical management of apparent stage I endometrial cancer
With the exception of patients managed conservatively,
extrafascial total hysterectomy without colpectomy is the main-
stay of management for patients with endometrial cancer. The
rationale for the additional removal of the adnexae is to prevent
ovarian cancer and rule out ovarian metastases. In premenopausal
patients, however, ovarian preservation may be discussed in
selected cases. Younger patients with endometrial cancer often
have early stage, low grade tumours. Thus, to avoid the short-
term and long-term consequences of surgical menopause, there
is a rationale for ovarian preservation in young women. Several
retrospective studies have recently provided evidence that ovarian
preservation has no statistically significant impact on the overall
survival (OS) of young patients with early-stage endometrial
cancer [72]. However, extreme care must be taken to rule out
synchronous concomitant ovarian malignancy.
Recommendation 4.6. Standard surgery is total hysterectomy
with bilateral salpingo-oophorectomy without vaginal cuffLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)Recommendation 4.7. Ovarian preservation can be considered in
patients younger than 45 years old with grade 1 EEC with myome-
trial invasion <50% and no obvious ovarian or other extrauterine
disease
ensus conference guidelinesLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)
566 Endometrial cancer consRecommendation 4.8. In cases of ovarian preservation, salpingec-
tomy is recommendedLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 4.9. Ovarian preservation is not recommended
for patients with cancer family history involving ovarian cancer
risk (e.g. BRCA mutation, LS, etc.). Genetic counselling/testing
should be offeredLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Minimally invasive surgical techniques
Hysterectomy and bilateral salpingo-oophorectomy can be car-
ried out using the open, laparoscopic or vaginal approach.
The largest randomised trial comparing laparoscopy to laparo-
tomy is the LAP2 study [73], which was designed to compare
laparoscopy versus laparotomy for comprehensive surgical
staging and management of stage I–IIA uterine cancer, including
hysterectomy, salpingo-oophorectomy, pelvic cytology and pelvic
and para-aortic lymphadenectomy. In this trial, patients were
randomly assigned to laparoscopy (n = 1696) or open laparotomy
(n = 920). A significantly longer operative time was reported for
the laparoscopy group compared with the laparotomy group
(204 vs 130 minutes, respectively). Intra-operative complication
rates were similar between groups. However, laparoscopy was
associated with significantly fewer moderate to severe post-
operative adverse events (14% vs 21%) and a lower frequency of
hospitalisations of more than 2 days (52% vs 94%) than laparo-
tomy. Although pelvic and para-aortic lymph nodes were not
removed in 8% and 4% of patients in the laparoscopy and laparo-
tomy groups, respectively (P < 0.0001), there was no difference in
the overall detection of advanced stage disease between the two
groups. The major shortcoming of this trial is the high conversion
rate related to its multicentric design. Indeed, 25.8% of patients
assigned to the laparoscopic group were converted to laparo-
tomy, with a statement of ‘poor visibility’ reported in 14.6% of
cases, reflecting the learning curve of some investigators, partic-
ularly for LND. In contrast, a conversion rate of 10.8%, with poor
visibility recorded as the main factor in 4.9% of cases, was
reported in a Dutch randomised trial in which no lymphadenec-
tomy was performed [74]. However, as further training or the use
of robotic assistance would likely have resulted in even better
results with laparoscopic surgery, this high conversion rate
reported in LAP2 does not weaken the authors’ conclusions, and
this trial provides evidence that laparoscopic surgical staging
for uterine cancer results in fewer complications and shorter
hospital stay.
According to a meta-analysis of data from eight randomised
controlled trials (RCTs) conducted by Zullo et al. [75], intra-
operative complication rates were not different between
laparoscopy and laparotomy (RR 1.25; 95% CI 0.99–1.56) with
no significant heterogeneity across the studies. Estimated blood
loss and haemoglobin or haematocrit changes were consistently
less after laparoscopy in the six studies where this was reported.
Operative time was higher by 34–74 min in the laparoscopy
group. The authors also found a significant advantage of laparo-
scopy over laparotomy in terms of post-operative complications
(RR 0.71; 95% CI 0.63–0.79) with significant heterogeneity across
the studies.Aortic dissection can also be achieved in obese patients using an
extraperitoneal laparoscopic approach [76].
Taken together, these findings provide definitive evidence of the
short-term benefit and cost-effectiveness of laparoscopic hysterec-
tomy in patients with gynaecological cancer. This includes patients
with comorbidities, obesity or advanced age. Regarding comorbid-
ity, Tozzi et al. [77] found that the surgical technique is the only
significant parameter associated with complication rate, regardless
of risk group, stressing the fact that patients with serious comor-
bidities benefit most from laparoscopy. The issue of advanced
age has also been addressed in the gynaecological oncology litera-
ture. Siesto et al. [78] reported outcomes from a series of 48
patients aged >65 years who had undergone laparoscopic surgery
for endometrial cancer. Outcomes from this group were compara-
ble to younger patients in terms of operative time, blood loss, need
for blood transfusions, nodal count and intra-operative and post-
operative complications. The authors conclude that in the absence
of absolute anaesthesia contraindications, laparoscopy is feasible
and safe in older women with endometrial cancer. However, as
cancer in older women was more frequently upstaged than in
younger women, they state that comprehensive surgical staging
should be offered, regardless of age, to avoid understaging and to
optimise treatment strategies.
Six randomised trials comparing outcomes after laparotomy ver-
sus laparoscopy are currently available, four of which have been
included inapublishedmetanalysis [79].However, only twoof these
four trials reported data for OS, disease-free survival and cancer-
related survival. Based on the availability of new data, this meta-
analysis was subsequently updated by Palomba et al. in 2009 [80]
to includea third trial reporting these long-termoutcomes, resulting
in a sample of 359 patients. No significant heterogeneity was
observed among these trials and there was no significant adverse
effect of a laparoscopic approach on the OS, disease-free survival
or cancer-related survival (OR 0.96, 0.95 and 0.91, respectively).
Long-term outcomes of the randomised controlled LAP2 trial
were published in 2012 [81]. The primary endpoint was non-
inferiority of the recurrence-free interval. Non-inferiority was
defined as no more than a 40% increase in the risk of recurrence
with laparoscopy comparedwith laparotomy. The estimated hazard
ratio (HR) for recurrence-free survival with laparoscopy versus
laparotomy was 1.14 (90% CI 0.92–1.46). Actual recurrence rates
were substantially lower than anticipated; the estimated 3-year
recurrence rate was 11.4% with laparoscopy and 10.2% with laparo-
tomy, and the estimated 5-year OS was almost identical in both
arms (89.8%).
Recommendation 4.10. Minimally invasive surgery is recom-
mended in the surgical management of low-and intermediate-
risk endometrial cancerLevel of evidence: I
Strength of recommendation: A
Consensus: 100% yes (37 voters)
In a retrospective, multi-institutional trial of patients with high
grade endometrial cancer, outcomes of 191 patients who under-
went laparotomy were compared with 192 patients who under-
went minimal invasive surgery. In this trial, women with high
grade endometrial cancer staged by minimally invasive techniques
experienced fewer complications and similar survival outcomes
compared with those staged by laparotomy [82].
Recommendation 4.11. Minimally invasive surgery can be con-
sidered in the management of high-risk endometrial cancerLevel of evidence: IV
Strength of recommendation: C
Consensus: 100% yes (37 voters)
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therapy
Although advances in surgical techniques, anaesthesiology and
peri-operative management mean that the vast majority of
patients with endometrial cancer are amenable to standard surgi-
cal therapy, a small proportion of patients are still medically unfit
for laparoscopic surgery or laparotomy. However, these patients
can still be managed either surgically by vaginal hysterectomy,
whenever possible, with bilateral salpingo-oophorectomy, or by
definitive RT, combining external beam radiation therapy (EBRT)
and brachytherapy, or by hormonal treatment. In addition,
vaginal hysterectomy is an acceptable minimally invasive surgical
option in some low-risk patients who do not need LND (see
Section 4).
Recommendation 4.12. Vaginal hysterectomy with salpingo-
oophorectomy can be considered in patients unfit for the recom-
mended surgery and in selected patients with low-risk endome-
trial cancerLevel of evidence: IV
Strength of recommendation: C
Consensus: 100% yes (37 voters)Recommendation 4.13. In medically unfit patients, RT or
hormone treatment can be consideredLevel of evidence: IV
Strength of recommendation: C
Consensus: 100% yes (37 voters)
5. What are the indications for and to what extent is
lymphadenectomy indicated in the surgical management of
endometrial cancer?
Surgical staging in apparent stage I EEC
Collection of peritoneal cytology was included as a staging pro-
cedure in earlier recommendations, but it is no longer considered
mandatory. However, since retrospective studies indicate that pos-
itive peritoneal cytology has prognostic value, collection of this
information could be considered, especially in patients with
tumours of non-endometrioid histology [83,84].
Recommendation 5.1. Peritoneal cytology is no longer considered
mandatory for stagingLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)
Lymphadenectomy
Lymphadenectomy is an integral part of the comprehensive sur-
gical staging of endometrial cancer. However, the role of lym-
phadenectomy in early endometrial cancer is unclear and
controversy remains regarding the indications for, the anatomic
extent of, and the therapeutic value of lymphadenectomy in the
management of the disease.
The definition of an adequate lymphadenectomy has not been
standardised: Current approaches include pelvic lymphadenec-
tomy, para-aortic lymphadenectomy to the inferior mesenteric
artery (IMA) and para-aortic lymphadenectomy up to the renal
vessels. Lymph node counts have become a marker for adequacy
of lymph node evaluation in a variety of solid tumour disease sites.
In endometrial cancer, two retrospective reviews have shown that
patients had improved survival when at least 10 to 12 lymph nodes
were removed during lymphadenectomy [85,86]. Lymph node
counts therefore provide a surrogate way of measuring the ade-quacy of a LND and, as such, more than 10 nodes should be
removed [87,88].
Sampling of lymph nodes has a low sensitivity in endometrial
cancer [89]. Indeed, it has been shown that para-aortic nodes
may be positive in the absence of positive pelvic nodes [90,91],
suggesting that para-aortic lymph nodes should be removed in
cases where a lymphadenectomy is indicated. In the Mayo Clinic
experience of 281 patients with endometrial cancer who under-
went lymphadenectomy, 22% of patients with high-risk disease
had lymph node metastases: 51% had both positive pelvic and
para-aortic nodes, 33% had positive pelvic lymph nodes only, and
16% had isolated para-aortic lymphadenopathy [92]. As the major-
ity (77%) of patients with para-aortic lymph node involvement had
metastases above the IMA, para-aortic lymphadenectomy up to the
renal vessels is recommended.
The concept of sentinel lymph node (SLN) dissection (SLND) was
first developed in cervical cancer as a tool to select patients most
suitable for surgical management. In low- and intermediate-risk
endometrial cancer, the rationale is different as the need for SLND
is controversial. However, SLND could represent a compromise
between no dissection (leaving a small proportion of node positive
patients) and full dissection (adding a useless procedure for the
majority of node-negative patients). In addition, ultrastaging of
the SLNs detects micrometastases otherwise undiagnosed by con-
ventional histology, even in patients considered at low risk, on the
basis of grade and depth myometrial invasion [93]. However, these
large series only use the cervix as the injection site. The question of
alternative injection sites in the endometrium or uterine fundus,
which are anatomicallymore logical, is still a topic for investigation.
Injection under hysteroscopic, ultrasound, laparoscopic or open
guidance in patients with endometrial cancer has been addressed,
without evidence of benefit of the more demanding and less
practical modalities. Nevertheless, evidence is accumulating that
the SLND may be useful in the management of endometrial
cancers [94].
Recommendation 5.2. If a lymphadenectomy is performed, sys-
tematic removal of pelvic and para-aortic nodes up to the level of
the renal veins should be consideredLevel of evidence: IV
Strength of recommendation: B
Consensus: 91.9% (34) yes, 2.7% (1) abstain, 5.4% (2) no (37
voters)Recommendation 5.3. SLND is still experimental, but large series
suggest that it is feasible. SLND increases the detection of lymph
nodes with small metastases and isolated tumour cells; however,
the importance of these findings is unclearLevel of evidence: IV
Strength of recommendation: D
Consensus: 100% yes (37 voters)Indications for lymphadenectomy
Although the therapeutic effect of lymphadenectomy is unclear,
it is an integral part of comprehensive staging. The advantages of
comprehensive surgical staging are a better definition of prognosis
and appropriate triage of patients for adjuvant therapy.
Data from two RCTs do not support the therapeutic benefit of
lymphadenectomy in early stage endometrial cancer. Benedetti-
Panici et al. randomised 514 women with clinical stage I endome-
trial cancer to either systematic pelvic lymphadenectomy or no
LND and found no improvement in disease-free survival or OS
between the two groups [95]. Similarly, the ASTEC trial, which
included 1408 patients with stage I endometrial cancer who were
randomised to receive surgical staging with or without pelvic
lymphadenectomy, failed to show a beneficial effect of
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data available, controversy still exists, partly due to criticisms of
the ASTEC trial, in which the number of lymph nodes removed
was low and systematic para-aortic lymphadenectomy was not
performed. A mathematical model applied to the ASTEC trial sug-
gested a survival difference of less than 2% between the experi-
mental and control arms under all circumstances [97]. This
model suggested that even if LND was therapeutic, this trial would
have been negative due to the trial design. In the Italian trial [95],
median node counts were 26, or 30 for the 26% of patients who also
had para-aortic lymphadenectomy, and there were no differences
in relapse rates, disease-free survival and OS.
In contrast, retrospective data, which are prone to selection bias
and stage migration, suggest that patients who underwent system-
atic lymphadenectomy had improved survival over those who had
limited or no sampling performed [88]. Data from 42,184 patients
with endometrial cancer, obtained from the Surveillance, Epidemi-
ology, and End Results Program of the US National Cancer Institute
for the years 1988–2003, showed that the average frequency of
LND was 31%, 40%, 47% and 53% for the years 1988–1991, 1992–
1995, 1996–1999 and 2000–2003, respectively (P < 0.0001) [98].
On multivariate analysis, the presence of LND was associated with
OS and uterine-specific survival benefits with HRs of 0.81
(P < 0.0001) and 0.78 (P < 0.0001), respectively, and removal
of >11 lymph nodes was associated with HRs of 0.74 (P < 0.0001)
and 0.69 (P < 0.0001), respectively. On the basis of these findings,
the authors concluded that the presence of LND and increased
number of nodes dissected predicted for improved OS and
uterine-specific survival in women with adenocarcinoma of the
endometrium.
Retrospective single institution studies advocate lymphadenec-
tomy for all grades of tumour [87,88]. In contrast, a series using a
US database supports lymphadenectomy for high-grade tumours
only [99]. This was confirmed by the SEPAL trial in a series of
intermediate- or high-risk patients with pelvic lymphadenectomy
with or without para-aortic LND [100]. Patients who underwent
para-aortic lymphadenectomy had a superior survival compared
with those who did not.
In addition to risk factors, the number of lymph nodes removed
also seems to be important, with higher node count associated with
improved survival [85,101]. Kim et al. recently analysed data from
nine trials (two RCTs and seven observational studies) involving
16,995 patients with endometrial cancer, and showed that the effi-
cacy of systematic lymphadenectomy, defined as removal ofP10–
11 lymph nodes, was associated with limited survival benefit in
patients with low-risk endometrial cancer, but resulted in
improved OS in patients with intermediate- or high-risk endome-
trial cancer [102]. However, patients with low-risk disease (i.e.,
grade 1 and 2 endometrioid lesions with <50% myometrial inva-
sion) have a very low probability of lymphadenopathy and there-
fore derive no benefit from a systematic lymphadenectomy [103].
Recommendation 5.4. Lymphadenectomy is a staging procedure
and allows tailoring of adjuvant therapyLevel of evidence: III
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 5.5. Patients with low-risk endometrioid carci-
noma (grade 1 or 2 and superficial myometrial invasion <50%) have
a low risk of lymph node involvement, and two RCTs did not show
a survival benefit. Therefore, lymphadenectomy is not recom-
mended for these patientsLevel of evidence: II
Strength of recommendation: A
Consensus: 100% yes (37 voters)Recommendation 5.6. For patients with intermediate risk (deep
myometrial invasion >50% or grade 3 superficial myometrial inva-
sion <50%), data have not shown a survival benefit. Lymphadenec-
tomy can be considered for staging purposes in these patientsLevel of evidence: II
Strength of recommendation: C
Consensus: 100% yes (37 voters)Recommendation 5.7. For patients with high risk (grade 3 with
deep myometrial invasion > 50%), lymphadenectomy should be
recommendedLevel of evidence: IV
Strength of recommendation: B
Consensus: 73.0% (27) yes, 8.1% (3) abstain, 18.9% (7) no (37
voters)Recommendation 5.8. Lymphadenectomy to complete staging
could be considered in previously incompletely operated high-
risk patients to tailor adjuvant therapyLevel of evidence: V
Strength of recommendation: C
Consensus: 100% yes (37 voters)
6. How radical should the surgery be in different stages and
pathological subtypes of endometrial cancer?
Surgical management of stage II–IV endometrial cancer
In a recent study from Japan, radical surgery in stage II endome-
trial cancer did not result in any survival benefit compared
with simple hysterectomy but was associated with more peri-
operative and late adverse events [104]. Another recent study
found that parametrial spread cannot be predicted by cervical
involvement alone but may be predicted by various lymphovascu-
lar space invasion (LVSI)-related histopathological factors [105].
However, radical hysterectomy is considered in cases of obvious
involvement of the parametrium. Surgery should then be tailored
according to the recent classification of radical hysterectomy
[106] in order to obtain free margins. Lymphadenectomy is
recommended.
Recommendation 6.1. Radical hysterectomy is not recommended
for the management of stage II endometrial cancerLevel of evidence: IV
Strength of recommendation: B
Consensus: 91.9% (34) yes, 8.1% (3) abstain (37 voters)Recommendation 6.2. Modified (type B) or type A radical hys-
terectomy should be considered only if required for obtaining free
marginsLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 6.3. Lymphadenectomy is recommended for
clinical or intra-operative stage II endometrial cancerLevel of evidence: IV
Strength of recommendation: B
Consensus: 97.3% (36) yes, 2.7% (1) abstain (37 voters)
Surgical management of stage III–IV endometrial cancer
Although there is no evidence from randomised trials for stage
III-IV endometrial cancer, there is consensus that multimodality
therapy is required, generally starting with radical cytoreductive
Table 2
New risk groups to guide adjuvant therapy use.
Risk group Description LOE
Low Stage I endometrioid, grade 1–2, <50% myometrial
invasion, LVSI negative
I




Stage I endometrioid, grade 3, <50% myometrial
invasion, regardless of LVSI status
I
Stage I endometrioid, grade 1–2, LVSI unequivocally
positive, regardless of depth of invasion
II
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significant advantage in progression-free survival (PFS) and OS
when optimal cytoreduction can be achieved [107]. However, not
all patients are amenable to optimal cytoreduction as a result of
poor general condition or tumour extent. In addition, the surgical
management of metastatic vaginal disease may impair the vaginal
function. Primary RT is therefore preferable in some cases.
Recommendation 6.4. Complete macroscopic cytoreduction and
comprehensive staging is recommended in advanced endometrial
cancerHigh Stage I endometrioid, grade 3, P50% myometrial
invasion, regardless of LVSI status
I
Stage II I
Stage III endometrioid, no residual disease ILevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (37 voters)Non endometrioid (serous or clear cell or
undifferentiated carcinoma, or carcinosarcoma)
I
Advanced Stage III residual disease and stage IVA I
Metastatic Stage IVB IRecommendation 6.5. Multimodality management should be
considered for the treatment of advanced endometrial cancer
when surgery may significantly impair vaginal functionFIGO 2009 staging used; molecular factors were considered but not included;
tumour size was considered but not included; nodal status may be considered for
treatment recommendations. LOE, level of evidence; LVSI, lymphovascular space
invasion.Level of evidence: IV
Strength of recommendation: B
Consensus: 97.3% (36) yes, 2.7% (1) abstain (37 voters)
Surgical management of non-EEC
The standard of surgical therapy in non-EEC is not different
from EEC (see Sections 3 and 5). Hysterectomy and bilateral
salpingo-oophorectomy is the mainstay of therapy in apparent
stage I disease. Radical hysterectomy is not recommended in stage
II disease, whereas complete cytoreduction is required in advanced
disease stages. However, there is no documentation on ovarian
preservation. Bilateral salpingo-oophorectomy is mandatory.
Comprehensive surgical staging of more advanced disease
stages is mandatory (see Section 5). Although no data from ran-
domised trials are available in non-EEC, the staging of apparent
stage I disease is similar to high-risk EEC. Omentectomy is also
considered in apparent stage I papillary serous carcinoma, in which
peritoneal implants are not uncommon. However, omentectomy is
not mandatory in cases of clear cell carcinoma [108], but should be
considered where there is a serous component since uterine sero-
sal spread has a negative impact on survival [109].
Recommendation 6.6. In non-EEC (apparent stage I), lym-
phadenectomy is recommendedLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)Recommendation 6.7. Staging omentectomy is not mandatory in
clear cell or undifferentiated endometrial carcinoma and
carcinosarcomaLevel of evidence: IV
Strength of recommendation: C
Consensus: 100% yes (37 voters)Recommendation 6.8. Staging omentectomy should be consid-
ered in serous carcinomaLevel of evidence: IV
Strength of recommendation: C
Consensus: 94.6% (35) yes, 5.4% (2) abstain (37 voters)
Adjuvant treatment
7. What is the current best definition of risk groups for adju-
vant therapy?
The majority of patients with endometrial cancer have a low
risk of recurrence and are managed by surgery alone [110]. Risk
groups have been devised based on clinicopathological prognosticfactors to identify patients at risk of recurrence who may benefit
from adjuvant therapy.
In order to have clinical value, a definition of risk groups should
have both prognostic value and consequences for the indication of
adjuvant therapy. Well defined clinicopathological prognostic fac-
tors include: Age, FIGO stage, depth of myometrial invasion,
tumour differentiation grade, tumour type (endometrioid versus
serous and clear cell) and LVSI [89]. Compared with the ESMO risk
group classification [8], the adverse prognostic role of both LVSI
and tumour grade 3 within the intermediate risk group (stage IA
grade 3 or stage IB grade 1–2) has been recognised [111–115]. This
has led to a new subdivision of low risk, intermediate risk and
high-intermediate risk in the current classification, which is differ-
ent from the risk classification used in many clinical trials. Histor-
ically, low-risk endometrial cancer was defined as endometrioid
adenocarcinoma FIGO stage I and grade 1 with superficial invasion
or grade 2 without invasion, and high-risk as stage I, grade 3 with
deep myometrial invasion, with other combinations of grade and
invasion defined as intermediate risk. Against this background,
the large trials evaluating the role of RT for intermediate-risk
endometrial cancer (PORTEC-1, GOG99, ASTEC/EN5, described
below [116–118]) were conducted, and based on the results of
these trials and a subsequent meta-analysis [119], a refined classi-
fication of low risk, intermediate risk and high-intermediate risk
has been introduced.
Factors such as tumour size and several molecular factors (e.g.
TP53, L1CAM) have been reported as having prognostic value in
observational studies but have not been incorporated into this
classification since they are still under investigation and currently
not in clinical use [120–124]. A definition of risk groups to identify
patients at risk of recurrence who may benefit from adjuvant ther-
apy has been devised by the consensus panel and is shown in
Table 2.8. What are the best evidence-based adjuvant treatment
strategies for patients with low- and intermediate-risk
endometrial cancer?
Although the 1988 FIGO staging system included surgical
staging, two large randomised trials have since found no benefit
of routine lymphadenectomy for nodal staging purposes in
low- and intermediate-risk endometrial cancer [95,96]. Given the
570 Endometrial cancer consensus conference guidelinesabsence of a survival benefit and its associated side effects, routine
lymphadenectomy is not recommended for low- and (high)
intermediate-risk disease in most national and international guide-
lines for these patients. The value of lymphadenectomy in high-
risk endometrial cancer is the subject of ongoing investigations.
Recommendations regarding what defines adequate (lymph node)
staging are detailed in the chapter on surgery.
Compared with the ESMO CPG on endometrial cancer [8], the
current recommendations are specified to address both scenarios
that surgical nodal staging is performed and is not performed,
and to specifically address non-endometrioid histological sub-
types. In addition, the roles of vaginal brachytherapy, EBRT and
chemotherapy, or combinations of these treatments, have been
specified in more detail for each of these situations.Low-risk endometrial cancer
Some patients now considered as low-risk were included in the
large randomised trials of adjuvant RT and no benefit of RT was
found in this subgroup [116–119]. A randomised trial of 645
patients with low-risk endometrial cancer treated with vaginal
brachytherapy also showed no advantage for the use of adjuvant
brachytherapy, likely because the risk of recurrence after surgery
alone is <5% [125]. Therefore, no adjuvant treatment is indicated
for patients with low-risk endometrial cancer.
Recommendation 8.1. In patients with low-risk endometrial
cancer (stage I endometrioid, grade 1–2, <50% myometrial
invasion, LVSI negative), no adjuvant treatment is recommendedLevel of evidence: I
Strength of recommendation: A
Consensus: 100% yes (37 voters)
Intermediate-risk endometrial cancer
Patients considered intermediate risk in the current classifica-
tion were included in the large randomised trials evaluating the
role of adjuvant RT in early-stage endometrial cancer [116–119].
In these trials, patients were randomised after total hysterectomy
with bilateral salping-oophorectomy to pelvic EBRT or observation
after surgery. All three trials and a meta-analysis by Kong et al.
[119] found that EBRT reduced the risk of pelvic recurrence by
threefold (from 14% to 4%), but did not lead to an OS benefit and
came at the cost of increased risk of (predominantly gastro-
intestinal) toxicity.
In contrast to the PORTEC-1 trial [117], surgical staging lym-
phadenectomy was mandatory in the GOG99 trial [118], showing
that for node-negative disease, EBRT still reduced the risk of recur-
rence. This risk reduction was mainly caused by prevention of local
(vaginal) recurrence. Both PORTEC-1 andGOG99defined a subgroup
of patients who derived the greatest benefit of adjuvant EBRT, a so-
called high-intermediate-risk group. In the PORTEC-1 trial, the def-
inition of risk groups was based on risk factors for locoregional
recurrence (age >60 years, deep [P50%]myometrial invasion, grade
3), with high-intermediate-risk patients defined as having two out
of three of these risk factors. In this subgroup, the 5-year risk of
locoregional recurrencewas 20% for observation versus 5% for adju-
vant RT, and only in this subgroup was the risk of relapse deemed
high enough to consider adjuvant RT [117]. In the GOG99 trial, the
definition of risk groups was based on risk factors for overall recur-
rence identified in previous Gynecologic Oncology Group (GOG)
studies, with high-intermediate-risk patients defined as: Age
<50 years and 1 risk factor, age 50–70 years and 2 risk factors, and
age >70 and all 3 risk factors. Similar resultswere found in theASTEC
trial, which reported a lower risk of vaginal and pelvic relapse in theno-EBRT group (7% vs 4% in the EBRT arm). In the ASTEC trial, vaginal
brachytherapy was allowed in both study arms, and more than 50%
of patients in the observation arm received vaginal brachytherapy.
The randomised PORTEC-2 trial included only patients with the
high-intermediate-risk factors defined in PORTEC-1, and showed
that vaginal brachytherapy provided excellent vaginal control
compared with EBRT, and had a more favourable toxicity and qual-
ity of life profile [126]. These results have been confirmed in a
Swedish trial in which vaginal brachytherapy was compared with
combined EBRT and a vaginal brachytherapy boost [127].
Multiple cohort studies have identified LVSI and grade 3 as risk
factors for disease recurrence [111–115]. This finding was con-
firmed in a recent pooled analysis of data from the PORTEC-1
and -2 trials, which showed that both LVSI and grade 3 are risk
factors for regional nodal recurrence and for distant metastasis
[128]. EBRT decreased the risk of regional nodal recurrence in this
small subgroup (5%) of patients, while vaginal brachytherapy did
not. Since the vast majority of patients in PORTEC-2 had grade
1–2 tumours with deep (P50%) myometrial invasion and without
LVSI, this population is now considered intermediate risk in the
current consensus classification. These patients have a low risk
of regional and distant recurrence, while their risk of local (vagi-
nal) recurrence is significantly decreased with adjuvant vaginal
brachytherapy. In addition, others have validated the added prog-
nostic value of the incorporation of LVSI in the ESMO risk classifi-
cation [129].
Because adjuvant RT does not improve OS and combined EBRT
and brachytherapy for recurrent disease is associated with a high
chance of complete remission, not performing routine adjuvant RT
is also an option [130]. However, combinedEBRT andbrachytherapy
for recurrent disease is associated with a higher rate of side effects
compared with adjuvant vaginal brachytherapy alone.
Recommendation 8.2. In patients with intermediate-risk
endometrial cancer (stage I endometrioid, grade 1–2, P50%
myometrial invasion, LVSI negative):1: Adjuvant brachytherapy is recommended to decrease vagi-
nal recurrence,
Level of evidence: I
Strength of recommendation: B
2: No adjuvant treatment is an option, especially for patients
aged <60 years
Level of evidence: II
Strength of recommendation: C
Consensus: 100% yes (37 voters)
High-intermediate-risk endometrial cancer
Patients with grade 1–2 tumours with deep (P50%) myometrial
invasion and unequivocally positive (substantial, not focal) LVSI,
and those with grade 3 tumours with <50% myometrial invasion
regardless of LVSI status, are referred to as high-intermediate-
risk in the current classification.
In the GOG249 study, both high-intermediate- and high-risk
patients were randomised between pelvic EBRT and vaginal
brachytherapy followed by chemotherapy (3 cycles of carboplatin
and paclitaxel). Results have been presented (abstract only) that
showed no PFS benefit of adjuvant chemotherapy over the stan-
dard EBRT [131].
Recommendation 8.3. In patients with high-intermediate-risk
endometrial cancer (stage I endometrioid, grade 3, <50% myome-
trial invasion, regardless of LVSI status; or stage I endometrioid,
grade 1–2, LVSI unequivocally positive, regardless of depth of
invasion):
and Oncology 117 (2015) 559–581 5711: Surgical nodal staging performed, node negative:
A. Adjuvant brachytherapy is recommended to decrease
vaginal recurrence
Level of evidence: III
Strength of recommendation: B
B. No adjuvant therapy is an option
Level of evidence: III
Strength of recommendation: C
Consensus: 100% yes (37 voters)
2: No surgical nodal staging:
A. Adjuvant EBRT recommended for LVSI unequivocally
positive to decrease pelvic recurrence
Level of evidence: III
Strength of recommendation: B
B. Adjuvant brachytherapy alone is recommended for
grade 3 and LVSI negative to decrease vaginal recurrence
Level of evidence: III
Strength of recommendation: B
Consensus: 100% yes (37 voters)
3: Systemic therapy is of uncertain benefit; clinical studies are
encouraged
Level of evidence: III
Strength of recommendation: C
Consensus: 94.6% (35) yes, 5.4% (2) abstain (37 voters)
9. What are the best evidence-based adjuvant treatment
strategies for patients with high-risk endometrial cancer?
In general, high-risk endometrial cancer is characterised by an
increased risk of pelvic recurrence and distant metastases that con-
tribute to the inferior outcomes of this group. However, high-risk
endometrial cancer represents a heterogeneous group of patients,
including both endometrioid and non-endometrioid tumour types
such as serous and clear cell, and ranges from stage IB grade 3
(with or without LVSI and with or without nodal staging) to more
advanced FIGO stages. Regardless of tumour type, the estimated 5-
year OS according to the 26th FIGO annual report is 85–90% for
stage I, 75–85% for stage II, 50–65% for stage III and 20–25% for
stage IV [132]. Among FIGO stage I patients, those with deep
myometrial invasion and grade 3 histology are at increased risk
of pelvic and distant relapse [133–135]. Estimated 5-year OS rates
in patients with P50% myometrial invasion and grade 3 tumours
(without nodal staging) were only 58%. Regarding non-
endometrioid tumour types, approximately 60–70% of patients
with uterine serous cancer have disease outside the uterus at the
time of presentation. The 5-year OS rate for patients with uterine
serous cancer is 20–25% versus 80% for all patients with endome-
trial cancer [136]. For these reasons, recommendations were made
for the following subgroups: Endometrioid stage I, grade 3 and
>50% myometrial invasion; endometrioid stage II; endometrioid
stage III without residual disease and non-endometrioid tumour
types. Recommendations for patients with advanced non-
resectable or residual disease are provided separately in the
‘Advanced and Recurrent Endometrial Cancer’ section of this
article.
External beam pelvic RT is the standard therapy for high-risk
patients and is indicated to maximise pelvic control. The addition
of chemotherapy, or replacement of radiation therapy by
chemotherapy, has been studied in several randomised trials. A
historic GOG randomised trial that included patients with high-
risk stage I and occult stage II disease found no benefit of adjuvant
doxorubicin after surgery and post-operative pelvic EBRT [137]. A
Japanese (JGOG 2033) and an Italian trial randomised patients with
high-risk endometrial cancer between pelvic EBRT and adjuvant
cyclophosphamide, doxorubicin, cisplatin (CAP) chemotherapy (3
and 5 cycles, respectively), and both trials found no difference in
N. Colombo et al. / RadiotherapyOS or disease-free survival (5-year OS: 85% vs 87% and 69% vs
66%, respectively) [138,139].
Results of a combined analysis of the NSGO 9501 / EORTC 55991
and MaNGO-ILIADE III randomised trials have been published
[140]. In this pooled analysis, the addition of adjuvant chemother-
apy (4 cycles of platinum-based chemotherapy given either before
or after RT) to adjuvant EBRT was associated with a significant
improvement in 5-year PFS (78% vs 69%, P = 0.009), and a trend
towards improved OS (82% vs 75%, P = 0.07). Findings from a sub-
group analysis suggested that the benefit of adjuvant chemother-
apy was restricted to patients with endometrioid tumours rather
than the 36% with serous or clear cell tumours. However, as this
was an unplanned and small subgroup analysis, no definite conclu-
sions can be drawn on the efficacy of adjuvant chemotherapy for
serous or clear cell cancers.
Promising results were found in the RTOG 9708 phase II study
in 46 patients using concurrent pelvic RT and two cycles of Cis-
platin (50 mg/m2 days 1 and 28) followed by four additional
courses at 28 day intervals of cisplatin (50 mg/m2) and paclitaxel
(175 mg/m2) as a 24 h infusion [141]. Reported 4-year OS rates
were 85% for the whole group and 77% for stage III patients. This
concurrent and adjuvant chemotherapy schedule formed the ratio-
nale for the treatment arms included in recently completed trials
that investigated the role of combined cisplatin-based chemoradi-
ation plus adjuvant chemotherapy compared with either RT alone
(PORTEC-3) or chemotherapy alone (GOG258) for patients with
high-risk and advanced stage endometrial cancer. The ongoing
ENGOT-EN2-DGCG/EORTC55102 trial is evaluating the role of
chemotherapy versus observation in patients with high-risk,
node-negative endometrial cancer.Recommendation 9.1. In patients with high-risk endometrial
cancer (stage I endometrioid, grade 3, P50% myometrial invasion,
regardless of LVSI status):1: Surgical nodal staging performed, node negative:
A. Adjuvant EBRT with limited fields should be considered
to decrease locoregional recurrence
Level of evidence: I
Strength of recommendation: B
B. Adjuvant brachytherapy may be considered as an alter-
native to decrease vaginal recurrence
Level of evidence: III
Strength of recommendation: B
C. Adjuvant systemic therapy is under investigation
Level of evidence: II
Strength of recommendation: C
Consensus: 100% yes (37 voters)
2: No surgical nodal staging:
A. Adjuvant EBRT is generally recommended for pelvic
control and relapse-free survival
Level of evidence: III
Strength of recommendation: B
B. Sequential adjuvant chemotherapy may be considered
to improve PFS and cancer specific survival (CSS)
Level of evidence: II
Strength of recommendation: C
C. There is more evidence to support giving chemotherapy
and EBRT in combination rather than either treatment
modality alone
Level of evidence: II
Strength of recommendation: B
Consensus: 100% yes (37 voters)
High-risk, stage II endometrial cancer
The definition of stage II endometrial cancer was changed in the
most recent FIGO 2009 staging system; tumours with endocervical
572 Endometrial cancer consensus conference guidelinesglandular involvement (previously stage IIA) were moved to
stage I as this has no prognostic impact [142,143]. As a result,
stage II now only includes tumours with cervical stromal invasion
[144].
Stage II tumours have been associated with an increased fre-
quency of deep myometrial invasion and grade 3 histology, making
it difficult to conclude if cervical invasion alone is the reason for
the observed higher risk of recurrence and lower OS compared
with stage I disease [145]. In a SEER analysis that included 1577
patients with stage II endometrial cancer, of which half had stro-
mal invasion, a multivariate analysis demonstrated no OS benefit
for radical compared with simple hysterectomy, while RT (inde-
pendently of the type of surgery) was associated with a survival
benefit [146].
Controversy exists regarding the role of additional vaginal
brachytherapy boost in combination with EBRT [147]. The indica-
tion for a brachytherapy boost is clear in the rare situation of a
tumour with positive vaginal margin. However, in the adjuvant
setting, it has historically been performed largely for stage II dis-
ease. In randomised trials conducted in patients with
intermediate-risk stage I endometrial cancer, there is no clear ben-
efit in terms of vaginal control among trials that included a vaginal
brachytherapy boost compared with those that did not, with low
recurrence rates of approximately 2% at 5-years after EBRT or vagi-
nal brachytherapy alone [126,127]. A SEER analysis conducted in
patients with stage IIIC endometrial cancer suggested a survival
benefit for patients with ‘direct extension’ of the tumour, but no
vaginal recurrence rates are available [148]. Other studies have
found no difference in local recurrence or OS rates among patients
with stage II endometrial cancer treated with or without vaginal
brachytherapy in addition to EBRT, but it was associated with
increased risk of side effects [149–153].
Recommendation 9.2. In patients with high-risk, stage II
endometrial cancer:1: Simple hysterectomy, surgical nodal staging performed,
node negative:
A. Grade 1–2, LVSI negative: Recommend vaginal
brachytherapy to improve local control
Level of evidence: III
Strength of recommendation: B
B. Grade 3 or LVSI unequivocally positive:
i. Recommend limited field EBRT
Level of evidence: III
Strength of recommendation: B
ii. Consider brachytherapy boost
Level of evidence: IV
Strength of recommendation: C
iii. Chemotherapy is under investigation
Level of evidence: III
Strength of recommendation: C
Consensus: 97.3% (36) yes, 2.7% (1) abstain (37
voters)2: Simple hysterectomy, no surgical nodal staging:
A. EBRT is recommended
Level of evidence: III
Strength of recommendation: B
B. Consider brachytherapy boost
Level of evidence: IV
Strength of recommendation: C
C. Grade 3 or LVSI unequivocally positive: Sequential adju-
vant chemotherapy should be considered
Level of evidence: III
Strength of recommendation: B
Consensus: 100% yes (37 voters)High-risk, stage III endometrial cancer
In patients with stage IIIC endometrial cancer, pelvic and/or
extended field RT have been associated with increased OS and
locoregional control rates, while a higher rate of pelvic recurrence
was found after adjuvant chemotherapy alone [154,155]. In the
GOG122 trial [156], women with advanced stage III/IV endometrial
cancer were randomised between whole abdominal irradiation and
8 cycles of doxorubicin/cisplatin chemotherapy. Both adjusted PFS
and OS were higher in the group who received chemotherapy (pre-
dicted 5-year rates of 50% vs 38% and 55% vs 42%, respectively).
However, event rates were high in both arms (50% and 54%).
Patients with up to 2 cm residual disease were included in this
trial, suggesting that the dose delivered with whole abdominal
irradiation is not effective for macroscopic disease and is toxic. In
view of findings from the pooled NSGO/EORTC/Iliace trials [140]
as well as results from prospective and retrospective trials
[141,154,155,157,158], the use of combined radiation therapy
and chemotherapy is recommended as opposed to either alone.
Results of the recently completed GOG258 for stage III-IV endome-
trial cancer are awaited to see if the combination of EBRT and
chemotherapy, as also evaluated in PORTEC-3, does indeed
improve PFS and OS compared with chemotherapy alone.Recommendation 9.3. In patients with high-risk, stage III
endometrial cancer and no residual disease:1: EBRT is recommended to:
A. Decrease pelvic recurrence
Level of evidence: I
Strength of recommendation: B
B. Improve PFS
Level of evidence: I
Strength of recommendation: B
C. Improve survival
Level of evidence: IV
Strength of recommendation: B
2: Chemotherapy is recommended to improve PFS and CSS
Level of evidence: II
Strength of recommendation: B
3: There is more evidence to give chemotherapy and EBRT in
combination than either alone in stage III disease:
A. IIIA: Chemotherapy AND EBRT to be considered
B. IIIB: Chemotherapy AND EBRT to be considered
C. IIIC1: Chemotherapy AND EBRT to be considered
D. IIIC2: Chemotherapy AND extended field EBRT to be
considered
Level of evidence: II
Strength of recommendation: B
Consensus: 94.6% (35) yes, 5.4% (2) abstain (37 voters)
High-risk, non-endometrioid cancers
For the purpose of these recommendations, serous, clear cell,
carcinosarcoma, undifferentiated and mixed (>10%) tumours are
regarded as high-risk non-endometrioid type cancers. These
tumours represent an infrequent subset of patients; hence most
studies are retrospective and have included a limited number of
patients. The largest retrospective study conducted to date sug-
gested a survival benefit for the combination of chemotherapy
and RT in uterine serous cancer [159]. However, a subgroup anal-
ysis of the NSGO 9501/EORTC 55991 and MaNGO-ILIADE III trials
did not show a survival benefit for patients with serous or clear cell
tumours [140]. Given the high rates of distant metastasis observed
in patients with uterine serous and clear cell tumours, adjuvant
chemotherapy can be considered and clinical trials addressing
these rare subtypes are encouraged [136,160]. One retrospective
study investigated the role of vaginal brachytherapy for stage I
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(26%) or had <50% myometrial invasion (58%), and 34% received
adjuvant chemotherapy. The 5-year rate of isolated pelvic recur-
rence was 4% and locoregional recurrence was 7%; the 5-year OS
rate was 84%, suggesting that vaginal brachytherapy alone is suffi-
cient in patients with stage IA disease [161].
Carcinosarcomas are regarded as metaplastic carcinomas con-
taining both sarcomatous and carcinomatous elements [162]. They
are rare and aggressive tumours with more than 35% of patients
presenting with extra-uterine disease at diagnosis and are associ-
ated with a 5-year OS rate of 50% for patients with stage I disease
[163]. In the EORTC-55874 trial, patients with stage I-II uterine sar-
comas were randomised to receive adjuvant RT after surgery. Of
the 224 patients included, 91 had carcinosarcoma. In both groups,
RT significantly reduced the risk of local relapse but there was no
difference in the rate of distant metastasis and OS [164]. Three
analyses of SEER data have been reported in this setting, which ini-
tially showed a survival benefit for patients who received RT but
who did not undergo lymphadenectomy [165,166]. However, in a
subsequent analysis, this survival benefit was not maintained
[167], thus limiting the conclusions that can be drawn from these
analyses. Finally, the GOG performed a trial in which whole
abdominal irradiation was compared with three courses of ifos-
famide and cisplatin after complete resection. In this trial,
chemotherapy was associated with a numerically lower risk of
recurrence and better survival but the differences were not
statistically significant [168].
Recommendation 9.4. In patients with high-risk, non-
endometrioid cancers:1: Serous and clear cell after comprehensive staging:
A. Consider chemotherapy; clinical trials are encouraged
Level of evidence: III
Strength of recommendation: B
B. Stage IA, LVSI negative: Consider vaginal brachytherapy
only without chemotherapy
Level of evidence: IV
Strength of recommendation: C
C. Stage PIB: EBRT may be considered in addition to
chemotherapy, especially for node positive disease
Level of evidence: III
Strength of recommendation: C
Consensus: 100% yes (37 voters)
2: Carcinosarcoma and undifferentiated tumours:
A. Chemotherapy is recommended
Level of evidence: II
Strength of recommendation: B
B. Consider EBRT; clinical trials are encouraged
Level of evidence: III
Strength of recommendation: C
Consensus: 94.6% (35) yes, 5.4% (2) abstain (37 voters)
Advanced and recurrent endometrial cancer
10. Does surgery or RT have a role in advanced or recurrent
endometrial cancer?Surgical cytoreduction
Patients with advanced disease (defined as bulky FIGO stage
IIIA–IV), or recurrent disease should only be considered for surgery
if it is anticipated that cytoreduction with no macroscopic residual
disease can be achieved. Cytoreduction also includes removal of
enlarged lymph nodes, but as there is no evidence that a system-
atic pelvic and para-aortal lymphadenectomy will influence PFS
or OS, it should not be routinely performed. In a meta-analysis of14 publications containing retrospective data from 672 patients,
median OS time was positively associated with an increasing pro-
portion of patients with no residual disease (each 10% increase
improved survival by 9.3 months, P = 0.04); the change in survival
for patients with between 0 and62 cm of disease after surgery was
not significant [169]. Exenteration may be considered for FIGO
stage IIIA and central local relapse. In selected cases, palliative sur-
gery can be performed to alleviate symptoms (e.g. bleeding or
bowel obstruction).
For patients with oligometastases or isolated retroperitoneal
lymph node metastases, surgical resection is an option that can
be considered but the evidence of its benefit is limited.
Recommendation 10.1. For patients with advanced or recurrent
disease, surgery is recommended only if optimal cytoreduction (no
residual disease) can be achieved. In selected cases, palliative
surgery is recommended to alleviate specific symptomsLevel of evidence: IV
Strength of recommendation: C
Consensus: 100% yes (37 voters)Recommendation 10.2. Exenteration can be considered in
selected patients with locally advanced tumours, and for isolated
central local relapse after radiation, if clear margins are expectedLevel of evidence: IV
Strength of recommendation: C
Consensus: 100% yes (37 voters)Recommendation 10.3. Complete resection of distant
oligometastases and pelvic or retroperitoneal lymph node relapse
can be considered if technically possible according to localisation
of diseaseLevel of evidence: V
Strength of recommendation: C
Consensus: 100% yes (37 voters)
Histology
Uterine serous cancer and clear cell cancer account for approx-
imately 10% and 3% of advanced endometrial cancer cases, respec-
tively [170]. Patients with advanced disease have a worse
prognosis than those with endometrioid type, but there is no evi-
dence that histology should influence the decision regarding
surgery.
Recommendation 10.4. Histological type should not influence the
decision whether or not to proceed with surgeryLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (37 voters)
RT for isolated vaginal relapse in early-stage endometrial cancer
RT is an effective therapeutic modality for improving local dis-
ease control. However, fewer patients now receive adjuvant radia-
tion for early disease. Observation after surgery particularly applies
to those with early stage, grade 1–2 disease without LVSI, as sal-
vage RT in those who have a localised vaginal relapse is associated
with good local control [171]. In the PORTEC1 trial, 35 of 39
patients with a vaginal recurrence after surgery alone were treated
with radical intent, mostly with combinations of EBRT and
brachytherapy, and in some cases with surgery. The complete
remission rate was 89%, and 77% remained disease free with a
median follow-up of 44 months [130]. Survival after relapse was
better in patients who did not receive primary adjuvant RT; among
patients who had received adjuvant RT, most relapses were at
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techniques of image-guided brachytherapy and intensity-
modulated RT (IMRT) are superior to conventional approaches,
although a single institution retrospective study of RT (EBRT pre-
dominantly using an IMRT technique followed by image-guided
high dose rate [HDR] brachytherapy) for vaginal recurrence has
also reported high tumour control rates [172].
Recommendation 10.5. RT with curative intent is indicated in
patients with isolated vaginal relapse after surgeryLevel of evidence: III
Strength of recommendation: A
Consensus: 100% yes (34 voters)
Chemotherapy with RT for recurrence
RT can be considered for patients with vaginal or pelvic nodal
recurrence. Improvements in RT techniques allow for better means
of localised treatment, or possibly retreatment of patients who
have previously received RT. Whether chemotherapy has an addi-
tional benefit is unclear. The ongoing randomised phase II
GOG0238 (NCT00492778) trial is comparing pelvic irradiation of
45 Gy in 25 fractions plus either brachytherapy or external beam
boost with the same schedule plus concomitant cisplatin (40 mg/
m2 weekly) in women with vaginal/pelvic relapse who have not
received prior RT.
Recommendation 10.6. For vaginal or pelvic nodal recurrence,
chemotherapy with RT could be considered in patients with high-
risk features for systemic relapseLevel of evidence: IV
Strength of recommendation: C
Consensus: 97.1% (33) yes, 2.9% (1) abstain (34 voters)
Combined approaches to recurrence and re-irradiation
The use of systemic therapy or surgery prior to RT for vaginal
or pelvic node recurrence could be considered in certain patients
with more bulky disease. As the techniques for image-guided
RT have improved, there are situations where re-irradiation
can be considered, although evidence from clinical trials is
lacking.
Recommendation 10.7. Use of systemic therapy or surgery prior
to RT for vaginal or pelvic node recurrence could be considered in
certain patientsLevel of evidence: V
Strength of recommendation: C
Consensus: 100% yes (34 voters)Recommendation 10.8. Re-irradiation could be considered in
highly selected patients using specialised techniquesLevel of evidence: V
Strength of recommendation: C
Consensus: 100% yes (34 voters)Palliative RT
RT can be effectively used to palliate symptoms such as bleed-
ing, bone metastases or painful nodal recurrence. No randomised
trials have been conducted comparing RT with palliative
chemotherapy.
Recommendation 10.9. RT is indicated for palliation of symptoms
related to local recurrence or systemic diseaseLevel of evidence: IV
Strength of recommendation: A
Consensus: 100% yes (34 voters)Radical RT for primary endometrial cancer
RT can be used as a primary treatment in patients with unre-
sectable disease, or where there are medical contraindications to
surgery [173,174]. Treatment involves intrauterine brachytherapy
alone or in combination with EBRT. Image guided brachytherapy
may improve outcomes [175]. Two year local control rates of more
than 90% can be achieved for medically inoperable stage I disease.
Recommendation 10.10. RT may be indicated for primary
tumours that are unresectable, or where surgery cannot be
performed or is contraindicated for medical reasonsLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (34 voters)
11. What are the optimal systemic therapies for advanced/
recurrent disease?
The majority of patients with advanced or recurrent disease will
be candidates for systemic palliative therapy. The choice between
hormonal treatment and chemotherapy relies on several factors,
including histopathological and clinical features of the individual
patient.Hormonal therapy: Which patient and when?
Hormonal therapy is indicated for patients with advanced or
recurrent endometrial cancer and endometrioid histology. This
statement is based on several clinical trials that have shown clini-
cal activity with a favourable toxicity profile [176,177].
Recommendation 11.1. Hormone therapy is indicated in
advanced or recurrent EECLevel of evidence: II
Strength of recommendation: A
Consensus: 100% yes (34 voters)
Response to hormonal therapy is quite variable, and a number
of pathological factors contributing to this variation have been
identified. For example, hormonal therapy is more likely to be
effective in grade 1 or 2 endometrioid tumours. In a large clinical
trial of MPA, the response rate was 37% for grade 1, 23% for grade
2 and 9% for grade 3 tumours [176]. Others have reported similar
findings [177]. Patients with hormone receptor positive disease
have also been shown to have a higher chance of responding to
endocrine therapy. In a randomised trial, the response rate
observed in patients with ER and PgR positive disease was around
25% and 37%, respectively, but was only 7–8% in patients with ER/
PgR negative disease [176,177]. Based on these results, it seems
that positivity of ER and/or PgR could be a predictive factor of
response to endocrine therapy and so should be determined before
initiating hormonal therapy.
Recommendation 11.2. Hormone therapy is more likely to be
effective in grade 1 or 2 endometrioid tumoursLevel of evidence: IV
Strength of recommendation: B
Consensus: 100% yes (34 voters)
Recommendation 11.3. Hormone receptor status should be
determined before hormone therapy is initiated, as it is more
likely to be effective in patients with positive PgR and ER statusLevel of evidence: III
Strength of recommendation: B
Consensus: 97.1% (33) yes, 2.9% (1) abstain (34 voters)
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be differences in hormone receptor status in the primary and
metastatic tumour. In a prospective collection of 686 primary
endometrial tumours and 171 metastatic lesions, loss of PgR
expression increased with disease progression, with 23% of pri-
mary tumours and 76% of metastatic lesions demonstrating PgR
loss [178].
Recommendation 11.4. Biopsy of recurrent disease could be
considered as there may be differences in hormone receptor status
in the primary and metastatic tumourLevel of evidence: III
Strength of recommendation: C
Consensus: 100% yes (34 voters)
Hormone therapy is the preferred front-line systemic therapy
for patients with hormone receptor positive grade 1 or 2 tumours
in the absence of rapidly progressive disease, as it provides an
excellent benefit/risk ratio and convenient toxicity profile. How-
ever, patients with visceral involvement and rapidly progressive
disease are not candidates for hormone therapy as it is not usually
associated with a rapid response.
Recommendation 11.5. Hormone therapy is the preferred front-
line systemic therapy for patients with hormone receptor positive
tumours – grade 1 or 2 and without rapidly progressive diseaseLevel of evidence: V
Strength of recommendation: A
Consensus: 100% yes (34 voters)
The progestogens, MPA 200 mg or MA 160 mg, are generally
recommended. They have shown clear activity for the front-line
treatment of non-selected patients with recurrent or persistent
endometrioid tumours not suitable for surgery or RT, with
response rates of around 25% and PFS times of 3 months
[176,179]. Data from a randomised trial comparing low (200 mg/-
day) versus high (1000 mg/day) dose MPA in 299 patients with
advanced or recurrent endometrial carcinoma showed that low-
dose MPA was more active than the high dose in terms of response
rate (25% vs 15%, respectively) and OS (11.0 vs 7.0 months, respec-
tively) [176].
Recommendation 11.6. Progestogens (e.g. MPA 200 mg or MA
160 mg) are generally recommendedLevel of evidence: III
Strength of recommendation: A
Consensus: 100% yes (34 voters)
Other endocrine therapies have also demonstrated activity in
phase II trials among patients with advanced or recurrent endome-
trial cancer, with tamoxifen, anastrozole and fulvestrant all associ-
ated with response rates of approximately 10% [180–182].
Interestingly, patients included in the anastrozole trial had not
received prior progestin therapy [182]. The combination of tamox-
ifen and MPA is associated with response rates and PFS similar to
MPA alone [183,184].
Recommendation 11.7. Other hormonal agents to consider after
progestins include tamoxifen, fulvestrant and aromatase inhibitorsLevel of evidence: III
Strength of recommendation: C
Consensus: 100% yes (34 voters)
Chemotherapy: Is there any standard of care?
Endometrial cancer is a relatively chemo-sensitive disease, with
anthracyclines, platinum-based drugs and taxanes shown to be themost active agents. Two clinical trials showed that the combina-
tion of cisplatin and doxorubicin was more active than doxorubicin
alone in terms of response rate (43–41% vs 17–25%) but with no
benefit in terms of OS [185,186]. The combination also resulted
in a higher incidence of grade 3–4 myelotoxicity and nausea/
vomiting.
In another GOG trial, conducted in patients with measurable
FIGO III–IV endometrial cancer, the addition of paclitaxel to cis-
platin and doxorubicin was associated with a higher response rate
and PFS than cisplatin and doxorubicin alone (objective response
rate [ORR]: 57% vs 34%, respectively, P < 0.01; median PFS: 8.3 vs
5.3 months, respectively, P < 0.01), and a small but significant
improvement in OS (median 15.3 vs 12.3 months, respectively,
P = 0.037) [187]. However, toxicity, especially peripheral neuropa-
thy, was significantly higher (grade 2–3: 39% vs 5%, respectively).
For this reason, it has not beenwidely adopted as a standard of care.
Finally, GOG209 was a randomised, non-inferiority trial that
compared the combination of paclitaxel 160 mg/m2, cisplatin
60 mg/m2 and doxorubicin 50 mg/m2 (TAP) with paclitaxel
175 mg/m2 and carboplatin AUC 6 (TC), both administered every
3 weeks. A total of 1305 patients were included in this trial, and
preliminary data (not yet fully published) indicate a similar
response rate (51.3% vs 51.2%) and PFS (median 13.5 vs
13.3 months) [188]. The median OS (primary study endpoint)
was 40.3 months for TAP and 36.5 months for TC, which met the
criteria of non-inferiority. TC had a more favourable toxicity profile
than TAP in this trial, with fewer patients discontinuing therapy
due to toxicity (12% vs 18%). In addition, TC can be administered
in the outpatient setting whereas TAP is given in the inpatient
setting in most countries. This aspect may be important in terms
of logistical, financial and quality of life considerations in the
palliative setting.
Recommendation 11.8. The standard of care is 6 cycles of three-
weekly carboplatin and paclitaxel. This is based on the preliminary
communication of a randomised trial showing similar efficacy and
less toxicity compared to cisplatin/doxorubicin/paclitaxelLevel of evidence: I
Strength of recommendation: A
Consensus: 100% yes (34 voters)
Evidence supporting the use of second line chemotherapy after
platinum-containing therapy in patients with endometrial cancer
is limited, especially in cases where the treatment-free interval fol-
lowing first line chemotherapy is less than 6–12 months. Although
various regimens have been evaluated in this setting [189–192], no
randomised trials have been published. Therefore, no specific reg-
imen can be recommended as a standard of care for second line
chemotherapy.
Recommendation 11.9. There is no standard of care for second
line chemotherapyLevel of evidence: V
Strength of recommendation: C
Consensus: 100% yes (34 voters)
12. What are the most promising targeted agents and which
study designs should be used to evaluate their clinical benefit?
Potentially ‘druggable’ molecular alterations in endometrial cancer
According to the WHO classification of endometrial carcinoma,
there are seven different types of tumours; however, endometrioid
carcinoma, grade 3 and serous carcinomas account for the vast
majority of aggressive tumours. Molecular genetic alterations
involved in the development of endometrioid cancers differ from
those of serous tumours and this must be taken into account when
576 Endometrial cancer consensus conference guidelinesdesigning clinical trials to evaluate the efficacy of molecular tar-
geted agents.
Over the last fifteen years, it has been demonstrated that
endometrial cancer shows microsatellite instability (MSI) and
mutations in PTEN, PIK3CA and KRAS, and that beta-catenin genes
are the most common molecular abnormalities in endometrioid
carcinomas, whereas serous tumours have alterations of p53 and
loss of heterozygosity on several chromosomes, as well as other
molecular alterations (STK15, p16, E-cadherin, and C-erbB2)
[193]. Recently, the TCGA Research Network performed an inte-
grated genomic characterisation of endometrial carcinoma [5].
The PI3K/AKT pathway is one of the most frequently altered sig-
nalling pathways in endometrioid tumours, often resulting from
mutations in PTEN, PIK3CA and PIK3RI [194]. Of particular interest
is the downstream effector, mammalian target of rapamycin
(mTOR), and inhibitors of mTOR are now undergoing evaluation
in clinical trials. The RAS-RAF-MEK-ERK signalling pathway also
plays an important role in these tumours, with frequent mutations
in KRAS, but also inactivation of tumour suppressors such as
RASF1A [195,196]. Fibroblast growth factor-2 (FGFR2) is mutated
in 10–14% of endometrioid tumours and is a target for receptor tyr-
osine kinase inhibitors [197]. Angiogenesis also plays a role in
endometrial tumourigenesis [198]. In addition, tumour homolo-
gous recombination and mismatch repair deficiencies are seen in
endometrioid tumours, the latter of which is particularly associ-
ated with LS, and these pathways could be interesting targets.
Although there are a large number of specific gene abnormali-
ties and aberrant signalling pathways that appear to be promising
targets, the frequency of each abnormality is small and this pre-
sents a challenge to evaluating therapies in clinical trials [199].
Examples include known tumour markers such L1CAM, Anexin 2,
other tyrosine kinase receptors (insulin-like growth factor receptor
[IGFR], epidermal growth factor receptor [EGFR]), and signalling
pathways involved in epithelial to mesenchymal transition (trans-
forming growth factor-beta [TGF-b], wnt) or stem cell-ness
(Notch). PI3K/PTEN/AKT/mTOR pathway, PTEN, MAPK-KRAS,
angiogenesis (especially FGFR2 and vascular endothelial growth
factor [VEGF]/VEGF receptor [VEGFR]), ER/PR and homologous
recombination deficiency (HRD)/MSI are altered in endometrial
cancer, and the relevance of these potential targets should be stud-
ied in clinical trials with targeted agents.
Recommendation 12.1. PI3K/PTEN/AKT/mTOR pathway, PTEN,
RAS-MAPK, angiogenesis (especially FGFR2 and VEGF/VEGFR),
ER/PgR and HRD/MSI are altered in endometrial cancer and
their relevance should be studied in clinical trials with targeted
agentsLevel of evidence: III
Strength of recommendation: B
Consensus: 100% yes (34 voters)
New agents in recurrent or metastatic endometrial cancer
The benefit of standard chemotherapy and hormonal therapies
is usually modest and of short duration. Currently, several different
targeted therapies are undergoing clinical evaluation but none are
currently licensed for use. EGFR, human epidermal growth factor
receptor-2 (HER2), mTOR and VEGFR inhibitors have been tested
in phase I and II trials, withmodest response rates [200–203]. How-
ever, since this consensus conference was held, findings from two
randomised phase II trials evaluating the addition of bevacizumab
to TC in advanced or recurrent endometrial cancer suggest that this
might be a promising approach worthy of further evaluation in
phase III clinical trials [204,205]. GOG-86P was a 3-arm trial evalu-
ating the addition of bevacizumab, temsirolimus or ixabepilone to
first line TC in 349 patients with advanced or recurrent endometrial
cancer [204]. No differences in PFS were seen when the three armswere compared with historical data for TC from GOG 209 [188].
However, bevacizumab appeared superior when the median OS
results were compared with these historical control data (34.0 vs
22.7 months, P < 0.039). In the MITO END-2 trial, which included
108 patients with advanced or recurrent endometrial cancer who
had received 0 or 1 prior lines of chemotherapy, bevacizumab
was added to 6–8 cycles of TC and then continued as maintenance
therapy. This approach resulted in a significant improvement in
median PFS (13 vs 8.7 months, P = 0.036) and a numerical increase
in median OS (23.5 vs 18 months, P = 0.24), although these OS data
are not yet mature [205].
Despite these promising results, few clinical trials of new tar-
geted therapies are molecularly driven [206] and the prevalence
of potential targets in metastatic lesions has been studied less than
in primary tumours [178].
Taken together, these findings suggest that PI3 Kinase, mTOR
and angiogenesis inhibitors are the most promising classes of
drugs to investigate in endometrial cancer [207], and progress in
this area is likely to be faster if studies are biomarker driven with
biopsy at entry.Recommendation 12.2. Drugs targeting PI3K/mTOR pathway
signalling and angiogenesis have shown modest activity but no
agent has been approved for clinical use, and further biomarker
driven studies are warrantedLevel of evidence: III
Strength of recommendation: A
Consensus: 100% yes (34 voters)
Clinical trial design
While clinical trial endpoints such as OS and PFS are desirable, it
may not be possible to make progress unless novel trial design and
endpoints are used. There should be better selection of patients,
using a more systematic approach to integration of biomarkers as
well as earlier characterisation and standardisation of diagnostic
imaging and biomarker assessments. Tumour response to biologi-
cal agents may not occur to the same degree as with chemotherapy
and alternative early endpoints, such as the percentage of patients
free from progression at 18 weeks [208], have been used. Trial
designs that include different gynaecological cancers of the same
histotype should also be considered, an approach that is being
taken in in the ongoing phase III GOG0261 trial of paclitaxel plus
carboplatin versus paclitaxel plus ifosfamide in patients with dif-
ferent types of gynaecological carcinosarcomas (NCT00954174),
and a randomised phase II trial of nintedanib versus chemotherapy
in patients with recurrent clear cell carcinoma of the ovary or
endometrium (EudraCT 2013-002109-73). There is also an
argument for not being too selective, as the presence of a specific
biomarker target may not be reflective of the probability of
response. In a recent analysis of phase II studies of mTOR
inhibitors, there was no correlation between response and the
presence of mutations in the PI3K-AKT pathway [209], a result that
could be explained by a variety of reasons, including the presence
of multiple mutations, cross-talk in the signalling pathways
involved, and the lack of re-biopsy samples to discount
discordance between the tumour mutation profile at diagnosis ver-
sus recurrence.
Setting up individual trials is both costly and time-
consuming, although adaptive phase II/III trials may offer some
advantages [210]. Alternative strategies such as the ‘basket’
approach, which includes all patients subdivided by specific his-
tological or molecular cohorts under the umbrella of a single
trial, may be the most efficient way forward [211]. Such trials
should also incorporate novel endpoints and the design would
be strengthened by the inclusion of sequential and repeated
assessments of biomarkers.
and Oncology 117 (2015) 559–581 577Recommendation 12.3. Clinical trial designs for new, targeted
therapy:1: Basket studies with multiple cohorts related to histological
subtypes and/or molecular alterations are considered a
priority
2: Biomarker driven clinical trials with biopsy at entry and
sequential biopsies in trials with molecular endpoints are
recommended
3: PFS or PFS at a defined time-point are the preferred primary
endpoints for early phase trials
4: OS is the preferred primary endpoint in phase III trials,
unless crossover is planned or expected
Level of evidence: V
Strength of recommendation: A
Consensus: 100% yes (34 voters)
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